Literature DB >> 7585510

Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene.

F Chen1, T Kishida, F M Duh, P Renbaum, M L Orcutt, L Schmidt, B Zbar.   

Abstract

Clear cell renal carcinomas are most frequently characterized by loss of function of both copies of the von Hippel-Lindau (VHL) disease gene, suggesting that the VHL gene product plays an important role in regulating renal cell proliferation. To directly assess the function of the VHL gene product, we transfected the wild-type VHL gene into two renal carcinoma cell lines that lacked normal expression of the gene. Expression of the wild-type VHL gene led to a dramatic suppression of growth in two renal carcinoma cell lines, A498 and UMRC6 in vitro, as measured by colony formation and direct cell counting. Transfection of a naturally occurring mutant VHL gene (nucleotide 713 G to A, Arg to Gln) did not lead to growth suppression of these renal carcinoma cells, nor did transfection of the wild-type VHL gene into two non-renal tumor cell lines that expressed the endogenous wild-type VHL gene. Expression constructs, which included the first ATG at nucleotide 214, were sufficient to produce the strongest growth suppression. These experiments provide direct evidence that the VHL gene product functions to suppress the growth of renal carcinoma cells and also provide a model for mapping the domains of the VHL protein important in suppressing tumor growth.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7585510

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

Review 1.  Gene therapy for urologic cancer.

Authors:  Fernando A Ferrer; Ronald Rodriguez
Journal:  Curr Urol Rep       Date:  2002-02       Impact factor: 3.092

2.  Expression and functional characterization of platelet-derived growth factor receptor-like gene.

Authors:  Feng-Jie Guo; Wei-Jia Zhang; Ya-Lin Li; Yan Liu; Yue-Hui Li; Jian Huang; Jia-Jia Wang; Ping-Li Xie; Guan-Cheng Li
Journal:  World J Gastroenterol       Date:  2010-03-28       Impact factor: 5.742

Review 3.  The molecular basis of von Hippel-Lindau disease.

Authors:  O Iliopoulos; W G Kaelin
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

4.  High cell density induces vascular endothelial growth factor expression via protein tyrosine phosphorylation.

Authors:  D Mukhopadhyay; L Tsiokas; V P Sukhatme
Journal:  Gene Expr       Date:  1998

Review 5.  Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma.

Authors:  Daniele Alesini; Claudia Mosillo; Giuseppe Naso; Enrico Cortesi; Roberto Iacovelli
Journal:  Ther Adv Urol       Date:  2015-10

6.  Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity.

Authors:  Jiabin An; Matthew B Rettig
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

Review 7.  Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.

Authors:  Randy L Jensen
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

8.  Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene.

Authors:  J R Gnarra; S Zhou; M J Merrill; J R Wagner; A Krumm; E Papavassiliou; E H Oldfield; R D Klausner; W M Linehan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

9.  Relevance of nuclear and cytoplasmic von hippel lindau protein expression for renal carcinoma progression.

Authors:  Peter Schraml; Alexander Hergovich; Florian Hatz; Mahul B Amin; So D Lim; Wilhelm Krek; Michael J Mihatsch; Holger Moch; Alexander Hergovitz
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

10.  Ubiquitin/SUMO modification regulates VHL protein stability and nucleocytoplasmic localization.

Authors:  Qiliang Cai; Erle S Robertson
Journal:  PLoS One       Date:  2010-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.